Skip to content

Advancing Oligonucleotide Method Development

Unlock the Future of Oligonucleotide Therapeutics with Sannova

In the rapidly evolving field of biotherapeutics, Oligonucleotides have emerged as a fait accompli in gene inhibition, holding unprecedented potential for targeting rare diseases that have been overlooked by conventional treatments.
 

Unlocking the Power of Sensitivity and Selectivity

To cast light on the crucial role of sensitivity and selectivity in the development of oligonucleotide therapeutics, we have compiled an in-depth whitepaper - "Mitigating Risks in Oligonucleotide Therapeutic Development: Unlocking the Power of Sensitivity and Selectivity." Register below to delve into this valuable resource.

body image siRNA (1)

What You Will Learn

When you download our free whitepaper, anticipate gaining:

  • Exclusive industry insights into the state of Antisense Oligonucleotides (ASOs), small interfering ribonucleic acids (siRNAs) and micro ribonucleic acids (miRNAs) therapy development.

  • Exploration of key challenges in oligonucleotide development.

  • An analytical guide to the intricate balance between sensitivity and selectivity in oligonucleotide therapeutic development.

  • Discussion of the importance of specialized bioanalytical and CMC support in successful therapeutic developments.

  • A case study demonstrating the sensitive and selective LCMS-MS HRMS analysis of Inclisiran

Sannova - Pioneering Progress in Biotherapeutics

Join us on our quest to redefine the possibilities of oligonucleotide therapeutic development. The time is now to unlock the power of sensitivity and selectivity in your research.
 

Download The Whitepaper

Discover how Sannova can partner with you to turn possibilities into reality. Engage today. Innovate for tomorrow.

Be a leader in your field—share our whitepaper on LinkedIn and empower your network with the knowledge to excel.

Share on LinkedIn